Krsnaa Diagnost.

Q1 FY27Healthcare Services

Krsnaa Diagnost. Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹558

Market cap₹1.8K Cr

P/E17.7

Updated23 Sept 2026

Read4 min read

What the Q1 FY27 call signalled

4 of 4 strong

RevenueGood growth

MarginMargins slightly up

CapexCapex planned

FundraiseFundraise planned

The short version

Volume Growth: Expected to continue growing both in retail and PPP segments, especially with underserved areas ramping up exponentially (Page 19). Rajasthan PPP project revenues expected to double in Q2 FY27, with annualized revenue guidance of INR100-150 crores, potentially reaching INR200-250 crores in aspirational terms.

From Krsnaa Diagnost.'s Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Good growth

Volume Growth: Expected to continue growing both in retail and PPP segments, especially with underserved areas ramping up exponentially (Page 19).
Rajasthan PPP Project: Revenue expected to double in coming quarters with a full-year target of INR100-150 crores, and aspirational target of INR200-250 crores (Pages 8-9).
Retail Business: Currently contributing around 8-9% of sales, anticipated to grow exponentially by the end of the financial year driven by new wellness and illness packages (Pages 15-16, 19).
New Projects: Expansion with additional PPP projects in pipeline including Himachal Pradesh and scaling up of MRI centers expected to contribute to top-line growth (Pages 15, 12).

2 more points management made on revenue & sales performance

Profitability & Margins

Rajasthan PPP project revenues expected to double in Q2 FY27, with annualized revenue guidance of INR100-150 crores, potentially reaching INR200-250 crores in aspirational terms.
Margin improvement anticipated as Rajasthan operations mature, with margins projected to return to double digits by year-end FY27.
Retail business showing strong momentum with 64% YoY growth; expected to grow exponentially by the end of FY27 and become EBITDA positive by Q2 FY27.
RPL (retail pathology labs) projected to achieve EBITDA breakeven by Q2 FY27, reducing overall margin drag.
Capital expenditures are front-ended; as utilization ramps up, profitability and margins expected to improve steadily.
Overall revenue growth driven by expansion in pathology, radiology (including MRI ramp-up), and new PPP projects (like Himachal Pradesh).

2 more points management made on profitability & margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

The company has raised funds via promoter infusion through warrants.
These funds are intended for capital expenditure related to ongoing projects and certain acquisitions planned by the company. (Page 10)
The infrastructure-led business model requires front-ended capital expenditure for building laboratories, installing equipment, and staffing teams before volume ramps up.
Investments have been made in building labs, diagnostic networks, and launching new MRI centers, especially highlighted in Rajasthan and other PPP projects. (Pages 5, 7, 12)

2 more points management made on capital expenditure plans

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹919 Cr

Rev 1Mar 1

2Chandan Healthca₹590 Cr

Rev 1Mar 3

3₹66.2K Cr

Rev 2Mar 1

4₹649 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The promoters have recently infused funds via warrants primarily for capital expenditure and potential acquisitions.
The fundraise through warrants was aimed at supporting project capital needs and acquisition plans.
There is no explicit mention of any new or upcoming fundraising through debt or equity beyond this warrant infusion in the provided transcript.

2 more points management made on fundraising & capital structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Rajasthan project is fully operational with 31 Mother labs, 62 hub labs, and 1,228 collection centers, offering significant future revenue visibility and scale.
Radiology expansion includes 17 MRI centers in the pipeline; 8 MRI centers in Maharashtra were inaugurated and operationalized in Q1 FY27.
Additional PPP projects in the pipeline beyond Rajasthan are expected to materialize and serve as new growth engines.
Retail business is expanding rapidly, with over 4,000 touchpoints across 7 states, leveraging an asset-light franchise model for growth.

2 more points management made on order book & pipeline

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹173 Cr, net profit ₹43 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Krsnaa Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
3B Blackbio DX Ltd (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Thyrocare Technologies Ltd (Q1 FY27)
Pathology business grew ~27%; franchisee business grew ~23-27% YoY, reflecting strong volume growth. Key concall takeaways from Thyrocare Technologies Ltd's Q1…
Artemis Medicare (Q1 FY27)
Potential to reach INR 2,000 crores topline from Gurgaon alone within 3-5 years. Key concall takeaways from Artemis Medicare's Q1 FY27 earnings call — and how…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Krsnaa Diagnost. Q1 FY27 results?

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 17.7 with a market cap of ₹1,755 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

The company has raised funds via promoter infusion through warrants.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.